Health ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Monoclonal Antibodies FDA Approval Obesity Treatments Semaglutide Lenacapavir Efficacy Studies Regulatory Approval Phase 3 Trials Osteogenesis Imperfecta Efzofitimod Innovative Treatments Retatrutide Market Claims Investigational Drugs Weight Loss Drugs Multiple Sclerosis Pfizer Setrusumab Simufilam Huntington's Disease Regulatory Affairs GLP-1 Drugs Rare Diseases Innovative Therapies Social Anxiety Disorder Novo Nordisk Safety Concerns Drug Simulation Preclinical Studies Product Efficacy Research and Development Long-acting Injectables Chronic Hepatitis B Therapeutic Candidates Psoriasis Treatment Growth Hormone Deficiency Breast Cancer Treatments Patient Outcomes Regenerative Medicine Products Baxdrostat FDA Regulations UK Healthcare System Data Protection Investor Impact FDA-Approved Drugs Virtual Testing Acoziborole Winthrop Drug Effectiveness Olezarsen ITI-1284 Nanobodies Biologics Market Competition Nimacimab Acoziborole Hypertension Treatments Antibiotics Alzheimer's Disease Fasedienol PALISADE-2 Trial Future Trends Feline Medications Regulatory Changes COVID-19 Vaccines Autoimmune Disorders Schizophrenia Lipid-Lowering Drugs Efficacy and Safety Weight-loss Medicines Zoliflodacin Efficacy Claims New Medications Peptide-Based Therapies Wegovy Methylenomicina A Tolebrutinib Type 2 Diabetes Immunology Biontech Experimental Treatments AI in Drug Design Male Contraceptive Trials Market Impact AbbVie Safety and Efficacy Gastroparesis Cancer Treatments Next-Generation Treatments Sodium Channel Blockers Prostate Cancer Medical Research Diabetes Treatments Jet Lag Medications Market Approval Drug Behavior Prediction Therapeutics Orphan Drug Designation Therapeutic Isotopes Antivenom Production PCSK9 Inhibitors FDA Approvals

Medicus Pharma Reports Long-Acting Hormone Control in Phase 1 Teverelix Data

The results give the company a basis to begin endometriosis studies with a genetics-led design alongside Omics Labs.

UniQure Investors Face Lead‑Plaintiff Deadline in Securities Fraud Case

Ultragenyx Hit With Securities Class Action Over Failed Phase III Trials

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

Insmed Sets $1 Billion 2026 Brinsupri Target After Strong First Full Quarter

NCI Pursues Preclinical Test of Ivermectin’s Anti-Cancer Activity

Lilly and Innovent Forge Territory-Split Cancer and Immunology Alliance

Vistagen Hit With Securities Class Actions After Phase 3 Miss as Investors Face March 16 Deadline

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

Law Firms Urge Telix Investors as Jan. 9 Lead-Plaintiff Deadline Nears

Skye Bioscience Faces Investor Class Actions as Firms Court Shareholders Before Jan. 16 Deadline

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years